The Europe Veterinary Vaccines Market would witness market growth of 5.3% CAGR during the forecast period (2023-2029).
The main reasons for the widespread acceptance of ruminants, especially cattle vaccinations, around the region are the rising outbreaks of cattle disease and the continuously growing livestock population. Animals are an essential source of food, protein, and other industrial goods like wool and leather. Equine influenza, foot & mouth disease, and rabies vaccinations are the three most frequently administered to animals. These vaccinations prevent the transmission of dangerous pathogens by imitating the body's naturally developed immunity.
The need for animal vaccines for the cattle population is rising due to growing concerns about food security and improved animal husbandry. In addition, livestock output has increased due to rising consumer demand for animal products. The demand for animal products is also rising due to a number of variables, including changes in food choices brought on through shifting lifestyles and population expansion, therefore such elements are contributing to the market's growth.
A zoonosis of growing clinical importance is the hantavirus illness. With more than 2800 cases reported, Germany's incidence peaked for the first time in 2012. These viruses can spread from small mammals to people. Clinically significant infections are brought on by two hantavirus species in Germany. Every two to three years, the Puumala virus, spread by bank voles, produces significant illness epidemics in Germany's southwest, west, and Bavarian forests. In addition, infections are brought on by the Dobrava-Belgrad virus, which striped field mice spread throughout the north and east of the nation. Thus, the demand is anticipated to rise in response to the rising prevalence of zoonotic diseases to prevent these illnesses from affecting the human population, supporting regional market expansion.
The Germany market dominated the Europe Veterinary Vaccines Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $755 million by 2029. The UK market is estimated to grow a CAGR of 4.4% during (2023 - 2029). Additionally, The France market would showcase a CAGR of 6.1% during (2023 - 2029).
Based on Route of Administration, the market is segmented into Injection Vaccines, Oral Vaccines and Intranasal/Spray Vaccines. Based on Type, the market is segmented into Livestock Vaccines, Porcine Vaccines, Companion Animal Vaccines, Poultry Vaccines, Aquaculture Vaccines and Others. Based on Technology, the market is segmented into Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Recombinant Vaccines and Others. Based on Distribution Channel, the market is segmented into Veterinary Hospitals, Veterinary Clinics and Retail Pharmacies. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Worldwide Veterinary Vaccines Market is Projected to reach USD 11.6 billion by 2029, at a CAGR of 5.8%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Zoetis, Inc., Merck & Co., Inc., Boehringer Ingelheim International GmbH, Elanco Animal Health, Inc., Virbac, Ceva Santé Animale, Neogen Corporation, Intas Pharmaceuticals Ltd. and Laboratoire LCV.
By Route of Administration
By Type
By Technology
By Distribution Channel
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
